[1]吴霏霏,杨君,许鑫.地诺孕素与促性腺激素释放激素激动剂联合替勃龙反向添加在子宫腺肌病保守手术后的应用效果比较[J].新乡医学院学报,2023,40(9):834-839.[doi:10.7683/xxyxyxb.2023.09.006]
　WU Feifei,YANG Jun,XU Xin.Comparison of application effect of dienogest and gonadotropin releasing hormone agonist combined with reverse addition of tibolone after the conservative surgery of adenomyosis[J].Journal of Xinxiang Medical University,2023,40(9):834-839.[doi:10.7683/xxyxyxb.2023.09.006]
点击复制

地诺孕素与促性腺激素释放激素激动剂联合替勃龙反向添加在子宫腺肌病保守手术后的应用效果比较
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
40卷
期数:
2023年9
页码:
834-839
栏目:
临床研究
出版日期:
2023-09-05

文章信息/Info

Title:
Comparison of application effect of dienogest and gonadotropin releasing hormone agonist combined with reverse addition of tibolone after the conservative surgery of adenomyosis
作者:
吴霏霏; 杨君; 许鑫
（新乡医学院第一附属医院妇科，河南　卫辉　453100）
Author(s):
WU Feifei; YANG Jun; XU Xin
(Department of Gynecology,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China)
关键词:
子宫腺肌病; 促性腺激素释放激素激动剂; 地诺孕素; 替勃龙; 反向添加
Keywords:
adenomyosis; gonadotropin releasing hormone agonist; dienogest; tibolone; reverse addition
分类号:
R711.74
DOI:
10.7683/xxyxyxb.2023.09.006
文献标志码:
A
摘要:
目的　比较地诺孕素（DNG）与促性腺激素释放激素激动剂（GnRH-a）联合替勃龙反向添加在子宫腺肌病保守手术后的应用效果。
方法　选择2020年3月至2021年3月于新乡医学院第一附属医院行腹腔镜下子宫腺肌病病灶切除术的100例患者为研究对象，根据术后应用的药物将患者分为观察组和对照组，每组50例。2组患者均于静脉复合全身麻醉下行腹腔镜下子宫腺肌病病灶切除术。对照组患者于术后2 d内给予GnRH-a制剂亮丙瑞林缓释微球3.75 mg，皮下注射，28 d注射1次，共注射6次；于GnRH-a第2次注射日开始，给予替勃龙片2.5 mg，口服，每日1 次，连续用药至最后1次注射亮丙瑞林缓释微球后28 d停药。观察组患者于术后2 d内开始给予DNG 2.0 mg，每日1 次，口服，连续用药6 个月。分别于治疗前、后，采用疼痛视觉模拟评分表 (VAS)评估2组患者痛经的疼痛程度；采集患者空腹肘静脉血，使用全自动电化学发光免疫分析仪检测血清糖类抗原125（CA125）、雌二醇（E2）水平；采用月经失血图评分法（PBAC）评估2组患者月经量。观察2组患者治疗期间潮热出汗、不规则阴道流血、失眠烦躁、肌肉骨关节疼痛等药物相关不良反应的发生情况，评估2组患者治疗后的临床治疗效果。
结果　对照组患者显效30例，有效18例，无效2例，总有效率为96.0%（48/50）；观察组患者显效27例，有效19例，无效4例，总有效率为92.0%（46/50）；2组患者总有效率比较差异无统计学意义（χ2=0.709，P>0.05）。治疗前、后，2组患者的VAS、PBAC评分及血清E2、CA125水平比较差异无统计学意义(P>0.05)。2组患者治疗后的 VAS、PBAC评分及血清E2、CA125水平显著低于治疗前 (P<0.01)。治疗期间，对照组患者发生潮热出汗8例（16.0%），不规则阴道流血2例（4.0%），失眠烦躁6例（12.0% ），肌肉骨关节疼痛5例（10.0%）；观察组患者发生潮热出汗 6例（12.0%），不规则阴道流血13例（26.0%），失眠烦躁7例（14.0%），肌肉骨关节疼痛6例（12.0%）；观察组患者不规则阴道流血发生率显著高于对照组(χ2=0.002，P<0.05)； 2组患者潮热出汗、失眠烦躁、肌肉骨关节疼痛发生率比较差异无统计学意义(χ2=0.564、0.766、0.749，P>0.05)。
结论　子宫腺肌病患者保守手术后，应用DNG与 GnRH-a 联合替勃龙反向添加疗法的临床效果相当，DNG治疗便捷性更高，更有利于提高患者的治疗依从性，可作为子宫腺肌病患者保守手术后的良好选择。
Abstract:
Objective　To compare the application efficacy of dienogest (DNG) and gonadotropin releasing hormone agonist (GnRH-a) combined with reverse addition of tibolone after the conservative surgery of adenomyosis.
Methods　A total of 100 patients who underwent laparoscopic resection of adenomyosis focus in the First Affiliated Hospital of Xinxiang Medical University from March 2020 to March 2021 were selected as the research objects.According to the drugs used after surgery,the patients were divided into observation group and control group,with 50 cases in each group.The patients in the both groups underwent laparoscopic resection of adenomyosis focus under intravenous combined general anesthesia.The patients in the control group received a subcutaneous injection of 3.75 mg of GnRH-a formulation leuprorelin sustained-release microspheres within 2 days after surgery,with one injection every 28 days,a total of 6 injections;on the second injection day of GnRH-a,2.5 mg of tibolone tablets were administered orally,once a day,continuously took drug until 28 days after the last injection of leuprorelin sustained-release microspheres.The patients in the observation group were given 2.0 mg of DNG orally within 2 days after surgery,once a day for 6 months.Before and after treatment,the severity of dysmenorrhea of patients in the two groups were evaluated by using visual analog scale (VAS);the fasting elbow vein blood was collected from patients,and the serum carbohydrate antigen 125 (CA125) and estradiol (E2) levels were detected by fully automatic electrochemical luminescence immunoassay analyzer;and the menstrual blood volumes of patients in the two groups were evaluated by using the psychological blood loss assessment chart (PBAC).The incidence of drug-related adverse reactions such as hot flushing and sweating,irregular vaginal bleeding,insomnia and irritability and muscle,bone and joint pain of patients during treatment in the two groups were observed.After treatment,the clinical efficacy of patients in the two groups was evaluated.
Results　In the control group,30 cases were excellent,18 cases were effective,2 cases were ineffective,and the total effective rate was 96.0%(48/50)；in the observation group,27 cases were excellent,19 cases were effective,4 cases were ineffective,and the total effective rate was 92.0% (46/50).There was no significant difference in the total effective rate of patients between the two groups (χ2=0.709,P>0.05).There was no significant difference in VAS,PBAC scores and serum E2,CA125 levels of patients between the two groups before and after treatment (P>0.05).The VAS,PBAC scores and serum E2 and CA125 levels of patients after treatment were significantly lower than those before treatment in the two groups (P<0.01).During treatment,8 patients (16.0%) had hot flushing and sweating,2 patients (4.0%) had irregular vaginal bleeding,6 patients (12.0%) had insomnia and irritability,and 5 patients (10.0%) had muscle,bone and joint pain in the control group;in the observation group,6 patients (12.0%) had hot flushing and sweating,13 patients (26.0%) had irregular vaginal bleeding,7 patients (14.0%) had insomnia and irritability,and 6 patients (12.0%) had muscle,bone and joint pain.The incidence of irregular vaginal bleeding of patients in the observation group was significantly higher than that in the control group (χ2=0.002,P>0.05);there was no significant difference in the incidences of hot flushing and sweating,insomnia and irritability and muscle,bone and joint pain of patients between the two groups (χ2=0.564,0.766,0.749;P>0.05).
Conclusion　The clinical effect of DNG is comparable to that of GnRH-a combined with tibolone reverse addition therapy in patients with adenomyosis after conservative surgery,DNG therapy is more convenient,and it is more beneficial to improve patients′ treatment compliance,so it can be used as a good choice for patients with adenomyosis after conservative surgery.

参考文献/References:

［1］　OTA I,TANIGUCHI F,OTA Y,et al.A controlled clinical trial comparing potent progestins,LNG-IUS and dienogest,for the treatment of women with adenomyosis［J］.Reprod Med Biol,2021,20(4):427-434.
［2］　李晟辉,赵虹.促性腺激素释放激素激动剂联合反向添加疗法对子宫内膜异位症患者维持雌激素水平的效果研究［J］.中国临床医生杂志,2020,48(7):857-859.
LI S H,ZHAO H.Effect of gonadin-releasing hormone agonist combined with reverse addition therapy on estrogen level maintenance in patients with endometriosis［J］.Chin J Clin,2020,48(7):857-859.
［3］　郭玲玲,郑娟,汪美香.腹腔镜手术联合GnRH-a治疗子宫腺肌症的疗效及对患者PGF2α、PGE2及β-内啡肽的影响［J］.中国妇幼保健,2020,35(2):369-371.
GUO L L,ZHENG J,WANG M X.Efficacy of laparoscopic surgery combined with GnRH-a in the treatment of adenomyosis and its effects on PGF2α,PGE2 and β-endorphin in patients［J］.Mat Child Health Care China，2020,35(2):369-371.
［4］　TAYLOR H S,DUN E C,CHWALISZ K,et al.Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management ofendometriosis-associated pain［J］.Pain Manag,2019,9(5):497-515.
［5］　ROMER T.Long-term treatment of endometriosis with dienogest:retrospective analysis of efficacy and safety in clinical practice［J］.Arch Gynecol Obstet,2018,298(4):747-753.
［6］　赵梦丹.不同促性腺激素释放激素激动剂治疗子宫内膜异位症的应用情况和疗效分析［J］.中国现代应用药学,2020,37(5):604-607.
ZHAO M D.Analysis of the treatment and efficacy of different gonadotropin-releasing hormone agonist for the treatment of endometriosis［J］.Chin J Mod Appl Pharm,2020,37(5):604-607.
［7］　MARIAN S,HERMANOWICZ-SZAMATOWICZ K.Endometriosis:a decade later-still an enigmatic disease.What is the new in the diagnosis and treatment［J］.Gynecol Endocrinol,2020,36(2):104-108.
［8］　RATHINAM K K,ABRAHAM J J,PREETHY H,et al.Evaluation of pharmacological interventions in the management of adenomyosis:a systematic review［J］.Eur J Clin Pharmacol,2022,78(4):531-545.
［9］　TOMASSETTI C,BAFORT C,VANHIE A,et al.Estimation of the endometriosis fertility index prior to operative laparoscopy［J］.Hum Reprod,2021,36(3):636-646.
［10］　COPE A G,AINSWORTH A J,STEWART E A,et al.Current and future medical therapies for adenomyosis［J］.Semin Reprod Med,2020,38(2/3):151-156.
［11］　JI M M,YUAN M,JIAO X,et al.A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea［J］.Gynecol Endocrinol,2022,38(2):164-169.
［12］　YAMAMOTO N,WADA-HIRAIKE O,HIRANO M,et al.Ovarian reserve may influence the outcome of bone mineral density in patients with long-term use of dienogest［J］.SAGE Open Med,2021,9(10):1-5.
［13］　LANG J,YU Q,ZHANG S,et al.Dienogest for treatment of endometriosis in chinese women:a placebo-controlled,randomized,double-blind phase 3 study［J］.Womens Health (Larchmt),2018,27(2):148-155.
［14］　DUEHOLM M.Minimally invasive treatment of adenomyosis［J］.Best Pract Res Clin Obstet Gynaecol,2018,51(18):119-137.
［15］　MORGANTE G,CAPPELLI V,LIBERA T,et al.Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome［J］.Eur J Contracept Reprod Health Care,2020,25(3):176-181.
［16］　SUARDIKA A,ASTAWA PEMAYUN T G.New insights on the pathogenesis of endometriosis and novel non-surgical therapies［J］.Turk Ger Gynecol Assoc,2018,19(3):158-164.
［17］　MIAO J,LU J,TANG J J,et al.Long-term treatment of dienogest with symptomatic adenomyosis:retrospective analysis of efficacy and safety in clinical practice［J］.Gynecol Endocrinol,2022,38(8):656-660.
［18］　ALCALDE A,ZAMORA M,GRACIA M,et al.Assessment of quality of life,sexual quality of life,and pain symptoms in deep infiltrating endometriosis patients with or without associated adenomyosis and the influence of a flexible extended combined oral contraceptive regimen:results of a prospective,observational study［J］.J Sex Med,2022,19(2):311-318.
［19］　邓惠文,曹丽,苏园园,等.地诺孕素对子宫腺肌病疗效的临床研究进展［J］.中国妇产科临床杂志,2022,23(3):329-331.
DENG H W,CAO L,SU Y Y.Progress of clinical research on the efficacy of dienogest in treating adenomyosis［J］.Chin J Clin Obstet Gynecol,2022,23(3):329-331.
［20］　YANG S,LIU Y,WEN J,et al.Clinical efficacy of dienogest versus levonorgestrel-releasing intrauterine system for adenomyosis［J］.Evid Based Complement Alternat Med,2022,2022(10):1-6.
［21］　OSUGA Y,HAYASHI K,KANDA S,et al.Long-term use of dieno-gest for the treatment of primary and secondary dysmenorrhea［J］.Obstet Gynaecol Res,2020,46(4):606-617.
［22］　MURJI A,KUTAY B,LENG J,et al.Use of dienogest in endometriosis:a narrative literature review and expert commentary［J］.Curr Med Res Opin,2020,36(5):895-907.
［23］　ONO N,ASANO R,NAGAI K,et al.Evaluating the safety of die-nogest in women with adenomyosis:a retrospective analysis［J］.J Obstet Gynaecol Res,2021,47(4):1433-1440.

相似文献/References:

[1]周玲生.子宫腺肌病178例临床病理分析[J].新乡医学院学报,2001,18(05):363.
[2]张译心,王秀美,薛晓玲.促性腺激素释放激素激动剂对保守性腹腔镜手术后卵巢子宫内膜异位症患者疼痛及生殖激素水平的影响[J].新乡医学院学报,2019,36(8):785.[doi:10.7683/xxyxyxb.2019.08.020]
　ZHANG Yi-xin,WANG Xiu-mei,XUE Xiao-ling.Effects of gonadotropin releasing hormone agonists on pain and reproductive hormone levels in patients with ovarian endometriosis after conservative laparoscopic surgery[J].Journal of Xinxiang Medical University,2019,36(9):785.[doi:10.7683/xxyxyxb.2019.08.020]
[3]刘曼曼,管一春,刘文霞,等.不同促排卵方案对卵巢储备功能减退患者体外受精-胚胎移植结局的影响[J].新乡医学院学报,2019,36(6):529.[doi:10.7683/xxyxyxb.2019.06.007]
　LIU Man-man,GUAN Yi-chun,LIU Wen-xia,et al.Effect of different ovarian stimulation methods on the outcome of in vitro fertilization-embryo transfer in patients with ovarian reserve dysfunction[J].Journal of Xinxiang Medical University,2019,36(9):529.[doi:10.7683/xxyxyxb.2019.06.007]
[4]王　艺,王世进,郭会敏.高强度聚焦超声技术和促性腺激素释放激素激动剂单独或联合治疗子宫腺肌瘤的临床疗效[J].新乡医学院学报,2021,38(3):285.[doi:10.7683/xxyxyxb.2021.03.017]
　WANG Yi,WANG Shijin,GUO Huimin.Clinical efficacy of high-intensity focused ultrasound technology and gonadotropin releasing hormone agonist alone or combination therapy in patients with adenomyoma[J].Journal of Xinxiang Medical University,2021,38(9):285.[doi:10.7683/xxyxyxb.2021.03.017]
[5]陈红霞,陈　霞,丁雪松,等.Ⅰ型子宫腺肌病患者放置左炔诺孕酮宫内节育系统前应用不同剂量米非司酮预处理疗效比较[J].新乡医学院学报,2021,38(12):1160.[doi:10.7683/xxyxyxb.2021.12.011]
　CHEN Hongxia,CHEN Xia,DING Xuesong,et al.Comparison of curative effect of different doses of mifepristone in pretreatment of type Ⅰ adenomyosis patients before placement of levonorgestrel-releasing intrauterine system[J].Journal of Xinxiang Medical University,2021,38(9):1160.[doi:10.7683/xxyxyxb.2021.12.011]
[6]涂　皎,牟　萌,古衡芳,等.左炔诺孕酮宫内缓释系统不同应用方法治疗子宫腺肌病疗效观察[J].新乡医学院学报,2019,36(1):033.[doi:10.7683/xxyxyxb.2019.01.007]
　TU Jiao,MOU Meng,GU Heng-fang,et al.Effect of different application methods of levonorgestrel intrauterine sustained-release system in the treatment of adenomyosis[J].Journal of Xinxiang Medical University,2019,36(9):033.[doi:10.7683/xxyxyxb.2019.01.007]
[7]王瑞歌,王世进.促性腺激素释放激素激动剂联合高强度聚焦超声治疗子宫腺肌病疗效观察[J].新乡医学院学报,2017,34(6):529.[doi:10.7683/xxyxyxb.2017.06.021]
　WANG Rui-ge,WANG Shi-jin.Effect of gonadotropin releasing hormone agonist combined with high intensity focused ultrasound in the treatment of patients with adenomyosis[J].Journal of Xinxiang Medical University,2017,34(9):529.[doi:10.7683/xxyxyxb.2017.06.021]

更新日期/Last Update: 2023-09-05